Reconciliation of GAAP to Non-GAAP Information
(dollars in millions)
|
| Years ended December 31, |
| Percent change |
| |||||||||
|
| 2002 |
| 2001 |
| 2000 |
| 2002 |
| 2001 |
| |||
|
|
|
|
|
|
|
|
|
|
|
| |||
International net sales, as reported |
| $ | 320.7 |
| $ | 271.3 |
| $ | 322.0 |
| 18.2 | % | (15.7 | )% |
Adjustment for Japan on a consolidated basis |
| 77.9 |
| 110.1 |
| 88.8 |
|
|
|
|
| |||
Net sales, as adjusted for Japan |
| 398.6 |
| 381.4 |
| 410.8 |
| 4.5 | % | (7.2 | )% | |||
Adjustment for foreign exchange at a constant rate |
| 16.4 |
| 12.0 |
| (22.5 | ) |
|
|
|
| |||
Net sales, as adjusted for Japan and foreign exchange |
| $ | 415.0 |
| $ | 393.4 |
| $ | 388.3 |
| 5.5 | % | 1.3 | % |
Schedule B
Reconciliation of GAAP to Non-GAAP Information
(dollars in millions)
|
| Cardiac |
| Critical |
| Vascular |
| Perfusion |
| Other |
| Total |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales, as reported December 31, 2000 |
| $ | 311.2 |
| $ | 217.3 |
| $ | 54.8 |
| $ | 206.7 |
| $ | 13.8 |
| $ | 803.8 |
|
Adjustment for Japan on a consolidated basis |
| 6.7 |
| 30.4 |
| 2.5 |
| 14.6 |
| 33.4 |
| 87.6 |
| ||||||
Net sales, as adjusted for Japan |
| 317.9 |
| 247.7 |
| 57.3 |
| 221.3 |
| 47.2 |
| 891.4 |
| ||||||
Adjustment for perfusion products divestiture |
| — |
| — |
| — |
| (29.4 | ) | — |
| (29.4 | ) | ||||||
Adjustment for perfusion services divestiture |
| — |
| — |
| — |
| (117.3 | ) | — |
| (117.3 | ) | ||||||
Adjustment for mechanical cardiac assist divestiture |
| — |
| — |
| — |
| (2.5 | ) | — |
| (2.5 | ) | ||||||
Adjustment for foreign exchange at a constant rate |
| (9.2 | ) | (7.2 | ) | (1.7 | ) | (2.0 | ) | (1.0 | ) | (21.1 | ) | ||||||
Adjusted Net Sales December 31, 2000 |
| $ | 308.7 |
| $ | 240.5 |
| $ | 55.6 |
| $ | 70.1 |
| $ | 46.2 |
| $ | 721.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales, as reported December 31, 2001 |
| $ | 329.0 |
| $ | 209.9 |
| $ | 49.3 |
| $ | 102.1 |
| $ | 1.8 |
| $ | 692.1 |
|
Adjustment for Japan on a consolidated basis |
| 9.6 |
| 35.3 |
| 3.0 |
| 20.5 |
| 40.7 |
| 109.1 |
| ||||||
Net sales, as adjusted for Japan |
| 338.6 |
| 245.2 |
| 52.3 |
| 122.6 |
| 42.5 |
| 801.2 |
| ||||||
Adjustment for perfusion products divestiture |
| — |
| — |
| — |
| (58.9 | ) | — |
| (58.9 | ) | ||||||
Adjustment for foreign exchange at a constant rate |
| — |
| 5.4 |
| 0.2 |
| 2.5 |
| 3.9 |
| 12.0 |
| ||||||
Adjusted Net Sales December 31, 2001 |
| $ | 338.6 |
| $ | 250.6 |
| $ | 52.5 |
| $ | 66.2 |
| $ | 46.4 |
| $ | 754.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales, as reported December 31, 2002 |
| $ | 365.9 |
| $ | 230.3 |
| $ | 51.3 |
| $ | 43.2 |
| $ | 13.3 |
| $ | 704.0 |
|
Adjustment for Japan on a consolidated basis |
| 9.1 |
| 20.8 |
| 2.0 |
| 15.4 |
| 29.9 |
| 77.2 |
| ||||||
Net sales, as adjusted for Japan |
| 375.0 |
| 251.1 |
| 53.3 |
| 58.6 |
| 43.2 |
| 781.2 |
| ||||||
Adjustment for foreign exchange at a constant rate |
| 1.4 |
| 7.5 |
| 0.3 |
| 4.8 |
| 5.8 |
| 19.8 |
| ||||||
Adjusted Net Sales December 31, 2002 |
| $ | 376.4 |
| $ | 258.6 |
| $ | 53.6 |
| $ | 63.4 |
| $ | 49.0 |
| $ | 801.0 |
|
2
Schedule C
Reconciliation of GAAP to Non-GAAP Information
Gross Profit as a Percentage of Net Sales
|
| Years ended December 31, |
| ||||
|
| 2002 |
| 2001 |
| 2000 |
|
|
|
|
|
|
|
|
|
Gross profit as a percentage of net sales, as reported |
| 57.5 | % | 53.2 | % | 47.3 | % |
|
|
|
|
|
|
|
|
Adjustment for Japan on a consolidated basis |
| 0.2 | % | 0.8 | % | 1.4 | % |
Adjustment for perfusion products divestiture |
| — |
| — |
| 0.6 | % |
Adjustment for perfusion services divestiture |
| — |
| 3.1 | % | 5.4 | % |
Adjustment for mechanical cardiac assist divestiture |
| — |
| — |
| 0.5 | % |
|
|
|
|
|
|
|
|
Gross profit as a percentage of net sales, as adjusted |
| 57.7 | % | 57.1 | % | 55.2 | % |
3
Schedule D
Reconciliation of GAAP to Non-GAAP Information
SG&A Expense as a Percentage of Net Sales
|
| Years ended December 31, |
| ||||
|
| 2002 |
| 2001 |
| 2000 |
|
|
|
|
|
|
|
|
|
SG&A Expense as a percentage of net sales, as reported |
| 32.4 | % | 29.4 | % | 26.8 | % |
|
|
|
|
|
|
|
|
Adjustment for Japan on a consolidated basis |
| 1.1 | % | 1.7 | % | 1.7 | % |
Adjustment for perfusion products divestiture |
| — |
| — |
| (0.3 | )% |
Adjustment for perfusion services divestiture |
| — |
| 1.7 | % | 2.9 | % |
Adjustment for mechanical cardiac assist divestiture |
| — |
| — |
| (0.1 | )% |
|
|
|
|
|
|
|
|
SG&A Expense as a percentage of net sales, as adjusted |
| 33.5 | % | 32.8 | % | 31.0 | % |
4
Schedule E
Reconciliation of GAAP to Non-GAAP Information
R&D Expense as a Percentage of Net Sales
|
| Years ended December 31, |
| ||||
|
| 2002 |
| 2001 |
| 2000 |
|
|
|
|
|
|
|
|
|
R&D Expense as a percentage of net sales, as reported |
| 9.3 | % | 7.9 | % | 6.8 | % |
|
|
|
|
|
|
|
|
Adjustment for Japan on a consolidated basis |
| (0.6 | )% | (0.7 | )% | (0.5 | )% |
Adjustment for perfusion products divestiture |
| — |
| — |
| (0.2 | )% |
Adjustment for perfusion services divestiture |
| — |
| 0.6 | % | 1.0 | % |
Adjustment for mechanical cardiac assist divestiture |
| — |
| — |
| (0.4 | )% |
|
|
|
|
|
|
|
|
R&D Expense as a percentage of net sales, as adjusted |
| 8.7 | % | 7.8 | % | 6.7 | % |
5
